Acceptable Blood Glucose Targets for Adults with Type 2 Diabetes on Metformin
For adults with type 2 diabetes taking metformin, target a fasting blood sugar of 80-130 mg/dL (4.4-7.2 mmol/L) and a post-prandial glucose <180 mg/dL (10.0 mmol/L) measured 1-2 hours after starting the meal. 1
Fasting Blood Sugar (FBS) Targets
The American Diabetes Association recommends a preprandial capillary plasma glucose target of 80-130 mg/dL for most nonpregnant adults with diabetes. 1
The lower limit was deliberately set at 80 mg/dL (not 70 mg/dL) to provide a safety margin and prevent overtreatment in patients using glucose-lowering medications like metformin. 1
Blood glucose <70 mg/dL represents clinically important hypoglycemia requiring immediate treatment with 15-20g of fast-acting carbohydrate. 1
Blood glucose <54 mg/dL indicates Level 2 hypoglycemia where neuroglycopenic symptoms begin—this represents serious, clinically important hypoglycemia. 1
Post-Prandial Glucose (PPG) Targets
The American Diabetes Association recommends peak postprandial capillary plasma glucose <180 mg/dL for most nonpregnant adults with diabetes. 1
Postprandial measurements should be taken 1-2 hours after the beginning of the meal, which generally captures peak glucose levels. 2, 1
The <180 mg/dL target has remained consistent across American Diabetes Association guidelines from 2004 through 2024, indicating strong consensus on this threshold. 1
For type 1 diabetes, the International Diabetes Federation recommends a slightly lower postmeal target of 9.0 mmol/L (160 mg/dL), but for type 2 diabetes the 180 mg/dL threshold is standard. 2
Monitoring Frequency and Timing
Individuals on intensive insulin therapy should check glucose before meals and snacks, at bedtime, occasionally postprandially, and before/during/after exercise. 1
For patients on metformin monotherapy without insulin, less frequent monitoring is acceptable—typically fasting glucose and occasional postprandial checks to assess control. 1
More frequent monitoring is reasonable when glycemia is unstable, patients are prone to hypoglycemia, or treatment changes are made. 1
Common Pitfalls to Avoid
Do not rely solely on fasting glucose or A1C to assess glycemic control—postprandial excursions can be missed entirely if you only check fasting values. 1
Avoid measuring postprandial glucose at inconsistent times; standardize at 1-2 hours after meal start to capture peak levels and allow meaningful comparison. 1
Do not ignore postprandial glucose when A1C goals are not met despite good fasting values—this indicates excessive postprandial excursions requiring specific intervention such as adding a prandial agent or adjusting meal composition. 1
Setting targets too low (<80 mg/dL fasting) increases hypoglycemia risk without clear benefit, particularly in older adults or those with comorbidities. 1
Clinical Context for Metformin Therapy
Metformin primarily reduces fasting glucose by decreasing endogenous glucose production, with more modest effects on postprandial glucose. 3, 4
In non-obese patients with type 2 diabetes, metformin reduced postprandial glucose levels similarly to the prandial insulin secretagogue repaglinide, supporting its use even when postprandial control is a concern. 4
Postmeal exercise (5 × 10-minute bouts of moderate-intensity walking) combined with metformin resulted in the lowest peak postprandial glucose excursions compared with either treatment alone—consider recommending postmeal physical activity to optimize postprandial control. 5
Metformin dosages of 1500-2000 mg daily provide maximal glycemic benefit; ensure patients are on adequate doses before concluding that targets cannot be met with monotherapy. 6